Universal premedication and therapeutic drug monitoring for asparaginase‐based therapy prevents infusion‐associated acute adverse events and drug substitutions-Reference-Cited by-同舟云学术

Universal premedication and therapeutic drug monitoring for asparaginase‐based therapy prevents infusion‐associated acute adverse events and drug substitutions

Published:2019-05-16 Issue:8 Volume:66 Page:
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatr Blood Cancer

Author:

Cooper Stacy L.¹²^ORCID,Young David J.¹²,Bowen Caitlin J.³,Arwood Nicole M.⁴,Poggi Sarah G.¹,Brown Patrick A.¹²

Affiliation:

1. Department of OncologyJohns Hopkins School of Medicine Baltimore Maryland

2. Department of PediatricsJohns Hopkins School of Medicine Baltimore Maryland

3. Institute of Human GeneticsJohns Hopkins School of Medicine Baltimore Maryland

4. Department of PharmacyJohns Hopkins Hospital Baltimore Maryland

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology and Child Health

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pbc.27797

Reference28 articles.

1. Influence of intensive asparaginase in the treatment of childhood non‐T‐cell acute lymphoblastic leukemia;Sallan SE;Cancer Res,1983

2. Use of ?-asparaginase in childhood ALL

3. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01

4. Antibody response to Escherichia coli L‐asparaginase. Prognostic significance and clinical utility of antibody measurement;Cheung NK;Am J Pediatr Hematol Oncol,1986

5. Asparagine depletion after pegylatedE. coli asparaginase treatment and induction outcome in children with acute lymphoblastic leukemia in first bone marrow relapse: A Children's Oncology Group study (CCG-1941)

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Asparaginase: Optimizing Efficacy and Minimizing Toxicity in Pediatric and AYA ALL/LBL;Clinical Lymphoma Myeloma and Leukemia;2024-09

2. Predictive factors for l-asparaginase hypersensitivity in pediatric acute lymphoblastic leukemia;International Journal of Hematology;2024-02-29

3. Lack of benefit from premedication for pegylated asparaginase during pediatric acute lymphoblastic leukemia/lymphoma therapy: A side‐by‐side comparison;Pediatric Blood & Cancer;2023-10-19

4. Toxicity of L-asparaginase drugs in acute lymphoblastic leukemia treatment;Oncohematology;2023-09-13

5. Treatment and outcomes of symptomatic hyperammonemia following asparaginase therapy in children with acute lymphoblastic leukemia;Molecular Genetics and Metabolism;2023-07